PILOCARPINE HYDROCHLORIDE TABLETS

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

PILOCARPINE HYDROCHLORIDE

Disponible desde:

METHAPHARM INC

Código ATC:

N07AX01

Designación común internacional (DCI):

PILOCARPINE

Dosis:

5MG

formulario farmacéutico:

TABLET

Composición:

PILOCARPINE HYDROCHLORIDE 5MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0107358009; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2020-10-14

Ficha técnica

_PILOCARPINE HYDROCHLORIDE TABLETS Product Monograph _
_Page 1 of 33 _
PRODUCT MONOGRAPH
PR
PILOCARPINE HYDROCHLORIDE TABLETS
5 MG
CHOLINOMIMETIC AGENT
Methapharm Inc
81 Sinclair Boulevard
Brantford, Ontario
N3S 7X6, Canada
Date of Revision:
October 13, 2020
Submission Control No.: 241563
_PILOCARPINE HYDROCHLORIDE TABLETS Product Monograph _
_Page 2 of 33 _
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................19
PHARMACEUTICAL INFORMATION
..........................................................................19
CLINICAL TRIALS
..........................................................................................................20
DETAILED PHARMAC